US Patent 11173177 Compounds for treatment of lipoprotein metabolism disorders
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+204 characters)
Article
Patent abstract
The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.
Edits on 31 Jul, 2023
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
111731770
Date of Patent
November 16, 2021
0Patent Application Number
163341310
Date Filed
September 20, 2017
0Patent Primary Examiner
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
111731770
Date of Patent
November 16, 2021
0Patent Application Number
163341310
Date Filed
September 20, 2017
0Official Website
Patent Primary Examiner
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
111731770
Date of Patent
November 16, 2021
0Patent Application Number
163341310
Date Filed
September 20, 2017
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 18 Nov, 2021
Golden AI
Edits made to:
Infobox (+7 properties)
US Patent 11173177 Compounds for treatment of lipoprotein metabolism disorders
Infobox
Is a
Patent jurisdiction
Patent number
11173177
Date of patent
November 16, 2021
Patent application number
16334131
Date Filed
September 20, 2017
Patent primary examiner
Find more entities like US Patent 11173177 Compounds for treatment of lipoprotein metabolism disorders
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
